Evidence map›Paper›PMID 26603537›Full record

ArticleGlycoconjugate journal2016

Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines.

Ana I Manzano, F Javier Cañada, Bárbara Cases, Sofia Sirvent, Irene Soria, Oscar Palomares, Enrique Fernández-Caldas, Miguel Casanovas, Jesús Jiménez-Barbero, José L Subiza

2 registry-linked trialsOpen access · hybridAbstract read
In one paragraph

Article in Glycoconjugate journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02661854 phase2unknown statusnot on this map

Double Blind, Placebo-controlled, Dose Finding, Prospective, Multicenter Clinical Trial for the Treatment of Rhinitis/Rhinoconjunctivitis Against a Mixture of Dermatophagoides Pteronyssinus and Dermatophagoides Farinae Allergen Extract

TypeinterventionalSponsorInmunotek S.L.Ran2016 to 2020Enrolled186ConditionsRhinitis, RhinoconjunctivitisArmsMM09 Mannosylated 5.000 subcutaneous, MM09 Mannosylated 10.000 subcutaneous, MM09 Mannosylated 30.000 subcutaneous, MM09 Mannosylated 50.000 subcutaneous, MM09 Mannosylated 5.000 sublingual
NCT05400811 phase3unknown statusnot on this mapstarted 2022, after this paper: background citation

Prospective, Randomised, DBPC, Double-dummy, Multicenter CT of Efficacy and Safety With IT in Patients With Controlled Mild to Moderate Allergic Asthma and Rhinitis/Rhinoconjunctivitis, Allergic to D. Pteronyssinus and/or D. Farinae.

TypeinterventionalSponsorInmunotek S.L.Ran2022 to 2025Enrolled400ConditionsHouse Dust Mite Allergy, Perennial Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic AsthmaArmsMM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL), Placebo subcutaneous, Placebo sublingual
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Characterisation ofJournal of fungi (Basel, Switzerland) · 2025
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ana I ManzanoCentro de Investigaciones Biológicas, Madrid, Spain.
F Javier CañadaCentro de Investigaciones Biológicas, Madrid, Spain.
Bárbara CasesInmunotek SL, Punto Mobi 5, Alcalá de Henares, Madrid, Spain.
Sofia SirventFacultad de Químicas, Universidad Complutense, Madrid, Spain.
Irene SoriaInmunotek SL, Punto Mobi 5, Alcalá de Henares, Madrid, Spain.
Oscar PalomaresFacultad de Químicas, Universidad Complutense, Madrid, Spain.
Enrique Fernández-CaldasInmunotek SL, Punto Mobi 5, Alcalá de Henares, Madrid, Spain.
Miguel CasanovasInmunotek SL, Punto Mobi 5, Alcalá de Henares, Madrid, Spain.
Jesús Jiménez-BarberoCentro de Investigaciones Biológicas, Madrid, Spain.
José L SubizaInmunotek SL, Punto Mobi 5, Alcalá de Henares, Madrid, Spain. jlsubiza@inmunotek.com.
Inmunotek (Spain) · ESCentro de Investigaciones Biológicas Margarita Salas · ESUniversidad Complutense de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy for treating IgE-mediated allergies requires high doses of the corresponding allergen. This may result in undesired side effects and, to avoid them, hypoallergenic allergens (allergoids) polymerized with glutaraldehyde are commonly used. Targeting allergoids to dendritic cells to enhance cell uptake may result in a more effective immunotherapy. Allergoids coupled to yeast mannan, as source of polymannoses, would be suitable for this purpose, since mannose-binding receptors are expressed on these cells. Conventional conjugation procedures of mannan to proteins use oxidized mannan to release reactive aldehydes able to bind to free amino groups in the protein; yet, allergoids lack these latter because their previous treatment with glutaraldehyde. The aim of this study was to obtain allergoids conjugated to mannan by an alternative approach based on just glutaraldehyde treatment, taking advantage of the mannoprotein bound to the polymannose backbone. Allergoid-mannan glycoconjugates were produced in a single step by treating with glutaraldehyde a defined mixture of allergens derived from Phleum pratense grass pollen and native mannan (non-oxidized) from Saccharomyces cerevisae. Analytical and structural studies, including 2D-DOSY and (1)H-(13)C HSQC nuclear magnetic resonance spectra, demonstrated the feasibility of such an approach. The glycoconjugates obtained were polymers of high molecular weight showing a higher stability than the native allergen or the conventional allergoid without mannan. The allergoid-mannan glycoconjugates were hypoallergenic as detected by the IgE reactivity with sera from grass allergic patients, even with lower reactivity than conventional allergoid without mannan. Thus, stable hypoallergenic allergoids conjugated to mannan suitable for using in immunotherapy can be achieved using glutaraldehyde. In contrast to mannan oxidation, the glutaraldehyde approach allows to preserve mannoses with their native geometry, which may be functionally important for its receptor-mediated recognition.

Indexed as

AllergensAntigen-Antibody ReactionsFungal PolysaccharidesHumansImmunoglobulin EPoaceaePollenSaccharomyces cerevisiaeVaccinesAllergensFungal PolysaccharidesImmunoglobulin EVaccinesAllergenAllergoidConjugationGlutaraldehydeMannanVaccine

Identifiers

PMID26603537
PMCPMC4722057
OpenAlexW2172943386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.